TABLE IV.
Demographic and clinical characteristics, and nasal mucus lipid mediators of AERD inflammatory clusters
| Characteristic | Cluster 1 | Cluster 2 | Cluster 3 | P value |
|---|---|---|---|---|
| No. | 10 | 14 | 6 | |
| Age (y) | 41.8 ± 12.4 | 50.0 ± 12.4 | 47.8 ± 14.4 | .37 |
| Sex: female, n (%) | 5 (50) | 6 (43) | 1 (17) | .40 |
| Race: white, no. (%) | 10 (100) | 10 (71) | 6 (100) | .26 |
| BMI (kg/m2) | 29.1 ± 7.0 | 30.6 ± 3.2 | 29.2 ± 4.1 | .73 |
| Allergic rhinitis, n (%) | 9 (90) | 9 (64) | 5 (83) | .31 |
| NCS, n (%) | 7 (70) | 11 (79) | 5 (83) | .81 |
| LTR, n (%) | 6 (60) | 10 (71) | 3 (50) | .64 |
| Prior surgery, n (%) | 6 (60) | 11 (79) | 4 (67) | .61 |
| No. of previous surgeries | 1.0 (0.0-1.8) | 1.0 (1.0-2.8) | 2.0 (0.5-4.3) | .48 |
| Mean eosinophils/hpf | 124 (96-257) | 157 (80-250) | 108 (95-120) | .59 |
| SNOT-22 score | 46.6 ± 24.6 | 56.7 ± 21.5 | 42.3 ± 18.0 | .31 |
| Rhinologic | 11.7 ± 4.9 | 16.8 ± 5.8 | 15.5 ± 4.5 | .15 |
| Extranasal | 8.7 ± 4.5 | 9.9 ± 2.5 | 8.5 ± 3.0 | .47 |
| Ear/facial | 7.6 ± 5.6 | 11.9 ± 5.4 | 6.3 ± 3.2 | .08 |
| Psychological | 13.0 ± 8.2 | 14.6 ± 8.4 | 9.0 ± 7.0 | .41 |
| Sleep | 12.3 ± 9.4 | 11.4 ± 6.4 | 8.2 ± 9.2 | .63 |
| CT score | 21.1 ± 2.9 | 20.5 ± 2.6 | 19.3 ± 3.9 | .53 |
| Asthma classification | .74 | |||
| Persistent | 9 (90) | 13 (93) | 6 (100) | |
| Intermittent | 1 (10) | 1 (7) | 0 (0) | |
| Asthma status | .61 | |||
| Mild | 2 (20) | 1 (7) | 0 (0) | |
| Moderate | 2 (20) | 1 (7) | 2 (33) | |
| Severe | 7 (70) | 12 (86) | 4 (67) | |
| 12,13-EpOME | 11,304 (6,495-14,686) | 4,065 (2,224-10,679) | 2,737 (747-10,859) | .03 |
| 9,10-DiHOME | 22.7 (8.6-25.8) | 4.7 (3.2-14.4) | 3.4 (2.0-4.7) | .04 |
| 12,13-DiHOME | 1.2 (0.2-3.7) | 1.7 (0.0-3.7) | 0.0 (0.0-2.2) | .48 |
| 9,10-EpOME | 402 (280-4,920) | 235 (131-401) | 156 (61-530) | .07 |
| 13-HODE | 15,896 (11,297-19,632) | 5,283 (3,880-15,353) | 4,767 (1,803-7,366) | .02 |
| 8-HETE | 38.0 (18.4-69.7) | 25.0 (20.1-41.6) | 51.5 (18.4-64.4) | .61 |
| 12-HETE | 590 (545-931) | 321 (205-516) | 283 (193-486) | .006 |
| 15-HETE | 5,790 (3,141-6,848) | 4,569 (2,508-7,080) | 1,788 (1,297-3,143) | .10 |
| 11,12-EET | 211 (166-272) | 237 (168-392) | 224 (155-270) | .76 |
| 14,15-EET | 882 (657-1,144) | 794 (532-972) | 456 (188-740) | .25 |
| 20-HETE | 102,474 (45,493-125,811) | 84,706 (39,573-128,811) | 32,647 (23,116-59,291) | .08 |
| TxB2 | 63.8 (19.3-90.5) | 13.4 (4.7-19.3) | 17.8 (8.4-27.7) | .03 |
| PGD2 | 44.2 (27.6-70.2) | 25.2 (11.4-67.4) | 12.5 (3.6-24.5) | .08 |
| 15-Keto-PGE2 | 1.3 (0.9-1.6) | 1.4 (0.5-1.8) | 1.1 (0.6-1.5) | .99 |
| PGE2 | 108.5 (75.8-155.8) | 96.7 (70.1-137.8) | 37.3 (23.1-113.6) | .30 |
| PGF2a | 23.1 (7.5-33.6) | 3.0 (0.0-12.8) | 10.8 (1.9-14.9) | .10 |
| 9a,11b-PGF2a | 14.9 (8.5-21.5) | 9.0 (0.0-20.9) | 6.2 (0.0-13.4) | .30 |
| LTB4 | 0.0 (0.0-11.2) | 1.9 (0.0-11.2) | 0.0 (0.0-4.7) | .90 |
| LTC4 | 47.7 (19.7-74.7) | 24.6 (2.8-55.5) | 30.2 (19.0-38.4) | .46 |
| LTD4 | 2.8 (0.2-4.1) | 1.2 (0.0-2.1) | 1.8 (0.4-2.3) | .53 |
| LTE4 | 4.4 (3.7-10.5) | 9.8 (4.6-13.4) | 4.5 (0.9-9.9) | .52 |
| Total CysLTs | 65.7 (32.0-82.6) | 29.0 (18.2-74.0) | 40.3 (19.4-76.7) | .41 |
AERD, Aspirin-exacerbated respiratory disease; BMI, body mass index; CT, computed tomography; LTR, leukotriene modifier; NCS, nasal corticosteroid.
Values are presented as means ± SDs or medians with interquartile ranges, depending on the normalcy of the data. All mediator levels are presented as ng/mL. Data are presented as medians with interquartile range. Differences between groups were assessed by using the Kruskal-Wallis test followed by Dunn’s test for multiple comparisons or χ2 analysis. Boldface text indicates a P value of less than .05.